Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 25552385)

  • 1. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.
    Kurebayashi J; Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T
    Cancer Sci; 2017 May; 108(5):918-930. PubMed ID: 28211214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
    Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
    Lee SJ; Jeong JH; Lee IH; Lee J; Jung JH; Park HY; Lee DH; Chae YS
    Anticancer Res; 2019 Feb; 39(2):751-758. PubMed ID: 30711954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Maynadier M; Basile I; Gallud A; Gary-Bobo M; Garcia M
    Oncol Rep; 2016 Aug; 36(2):1127-34. PubMed ID: 27373750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR; Murphy LC; Hall RE; Sutherland RL
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
    Ehlers EM; Schubert C
    Ann Anat; 1999 May; 181(3):231-6. PubMed ID: 10363104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
    Abbas Abidi SM; Howard EW; Dmytryk JJ; Pento JT
    Clin Exp Metastasis; 1997 Jul; 15(4):432-9. PubMed ID: 9219732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
    Osborne CK; Boldt DH; Estrada P
    Cancer Res; 1984 Apr; 44(4):1433-9. PubMed ID: 6704960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of eribulin for the treatment of metastatic breast cancer.
    Perez-Garcia JM; Cortes J
    Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.